Drug
Nusinersen clinical trials
Also written BIIB058, Spinraza and ISIS 396443.
- studies test it
- 19
- open now
- 3
- in phase 3
- 7
- first study started
- 2011
Keep track of what changes. Save the nusinersen studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 5
- Phase 2
- 4
- Phase 3
- 7
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 4
Biogen (15) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · CHU de Reims (1) · NYU Langone Health (1)
Studies
Open first, then newest update. How each study uses nusinersen is read from its arms, and is right about nine times in ten.
Testing it · 19
- An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB058)Not yet recruitingPhase 3London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT07846696Written as Nusinersen Injectable Product
- An OLIP Study (Open Label Individual Patient) of Nusinersen in a Participant With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With NusinersenNot yet recruitingNot applicableLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNCT07838779Written as Nusinersen Injectable Product
- A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)RecruitingPhase 1BiogenNCT06555419Written as Nusinersen
- A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)CompletedPhase 3BiogenNCT04729907Written as Nusinersen
- A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam (ASCEND)Active, not recruitingPhase 3BiogenNCT05067790Written as Nusinersen
- A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular AtrophyCompletedPhase 2BiogenNCT02386553Written as Nusinersen
- A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec (RESPOND)CompletedPhase 4BiogenNCT04488133Written as Nusinersen
- Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyCompletedPhase 3BiogenNCT04089566Written as Nusinersen
- Study of the Functional Effects of Nusinersen in 5q-spinal Muscular Amyotrophy Adults (SMA Type 2 or 3 Forms)CompletedNot applicableCHU de ReimsNCT04576494Written as Nusinersen
- A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational StudiesCompletedPhase 3BiogenNCT02594124Written as nusinersen
- Pulmonary Function Test Changes and Respiratory Muscle Strength Trends in Spinal Muscular Atrophy Patients Receiving Nusinersen TreatmentsWithdrawnEarly Phase 1NYU Langone HealthNCT04050852Written as Nusinersen Treatments
- An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular AtrophyCompletedPhase 1/2BiogenNCT01703988Written as Nusinersen
- An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA)CompletedPhase 1BiogenNCT01494701Written as nusinersen
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)CompletedPhase 3BiogenNCT02292537Written as Nusinersen
- A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)CompletedPhase 2BiogenNCT01839656Written as nusinersen
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular AtrophyTerminatedPhase 3BiogenNCT02193074Written as nusinersen
- A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).TerminatedPhase 2BiogenNCT02462759Written as Nusinersen
- An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)CompletedPhase 1BiogenNCT02052791Written as nusinersen
- An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)CompletedPhase 1BiogenNCT01780246Written as nusinersen
Given in every arm · 1 — nusinersen is usual care beside what is tested
Codes
What other systems call nusinersen · ClinicalTrials.gg INT000051
- MeSH (NLM) C000590926nusinersenConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 5Z9SP3X666NUSINERSENConfirmed FDA, NLM
- RxNorm 1863556One source FDA
- NCI Thesaurus C166875NusinersenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000590926 | nusinersen | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 5Z9SP3X666 | NUSINERSEN | Confirmed FDA, NLM |
| RxNorm | 1863556 | — | One source FDA |
| NCI Thesaurus | C166875 | Nusinersen | One source FDA |
Also registered as nusinersen sodium (UNII 4CHB7QQU1Q).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.